Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Leukemia & Lymphoma|March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemiaRyan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Blood|April 7, 2006
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome predictionCarla S Wilson, George S Davidson, Shawn B Martin, et al.
Blood|May 5, 2016
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AMLJulia E Maxson, Rhonda E Ries, Yi-Cheng Wang, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Leukemia & Lymphoma|March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemiaRyan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Blood|April 7, 2006
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome predictionCarla S Wilson, George S Davidson, Shawn B Martin, et al.
Blood|May 5, 2016
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AMLJulia E Maxson, Rhonda E Ries, Yi-Cheng Wang, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Pageof 21